Long-Term Consequences of Hepatitis C Viral Clearance on the CD4 (+) T Cell Lymphocyte Course in HIV/HCV Coinfected Patients by J. Dazley, R. Sison, J. Slim

“…We retrospectively enrolled HIV/HCV-coinfected patients on HIV medications and treated for hepatitis C. CD4 + T cell counts were registered at baseline and after hepatitis C therapy. …”
Get full text

Ocular manifestations and treatment safety in hepatitis C patients undergoing direct-acting antiviral therapy: a prospective cohort study by Guilherme Thomé de Carvalho, Carlos Eduardo Brandão Mello, Kelma Macedo Pohlmann Simões, Mário Martins dos Santos Motta, Max Kopti Fakoury, Bruno Vasconcelos Coimbra, Laura Gomes Nunes Melo, Flávio Mac Cord Medina

“…Methods: A prospective cohort study was conducted involving chronic hepatitis C patients undergoing direct-acting antiviral therapy. …”
Get full text

Seroprevalences of Hepatitis B Virus and Hepatitis C Virus among Participants of an Asian Health Fair in the Lower Mainland, British Columbia by Stephen Ip, Jo-Ann Ford, Kirby Lau, Vladimir Marquez, Marisa Guan, Carolyn Klassen, Jessica Chan, WC Peter Kwan, Mel Krajden, Eric M Yoshida

“…BACKGROUND: The seroprevalences of hepatitis B virus (HBV) and hepatitis C virus (HCV) are 0.4% and 0.8%, respectively, in Canada, but varying rates have been reported in different populations.…”
Get full text

A Novel Use of Early Radiation Therapy in the Treatment of Hyperbilirubinemia in a Patient with Primary Hepatic Lymphoma and Chronic Hepatitis C by Venkata S. Tammana, Rehana Begum, Patricia Oneal, Hemamalini Karpurapu, Amruta Muley, Sri Lakshmi Hyndavi Yeruva, Jacquelyn Dunmore-Griffith, Eyasu Mekonen, Nabhani Hasan

“…Here, we describe a case of Hepatitis C virus infection with primary hepatic lymphoma (PHL) presenting with hyperbilirubinemia. …”
Get full text

Early Changes in Hepatitis C Virus (HCV) RNA Levels Predict Response to Interferon Treatment in Non-Cirrhotic HCV Patients by Glen Fallows, Kelly Kaita, Gerald Minuk, Faye Penner, Gerry Smart, Magdy Dawood, Barry Rosser

“…The role of hepatitis C virus (HCV) RNA quantification in determining ideal interferon (IFN) treatment of noncirrhotic HCV liver disease is uncertain. …”
Get full text

Hepatitis B prevalence in an endemic area of hepatitis C virus: A population-based study implicated in hepatitis elimination in Thailand by Nawarat Posuwan, Rujipat Wasitthankasem, Napaporn Pimsing, Wijittra Phaengkha, Saranya Ngamnimit, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Maneerat Raksayod, Yong Poovorawan

Get full text

Increased Duodenal Iron Absorption through Upregulation of Ferroportin 1 due to the Decrement in Serum Hepcidin in Patients with Chronic Hepatitis C by Masanori Sato, Koji Miyanishi, Shingo Tanaka, Akira Sakurada, Hiroki Sakamoto, Yutaka Kawano, Kohichi Takada, Masayoshi Kobune, Junji Kato

“…Hepatic iron accumulation is generally increased in the chronic hepatitis C (CHC) liver; however, the precise mechanism of such accumulation remains unclear. …”
Get full text

Pilot Study of Ofloxacin and Interferon-Alpha Combination Therapy for Chronic Hepatitis C without Sustained Response to Initial Interferon Therapy by Masafumi Komatsu, Tohru Ishii, Tsuyoshi Ono, Takao Hoshino, Tomoyuki Kuramitsu, Takashi Goto, Tomoo Fujii, Itaru Toyoshima, Mitsuro Chiba, Osamu Masamune

“…A controlled trial comparing combination therapy with ofloxacin (OFLX) and interferon (IFN) versus IFN monotherapy was conducted in patients with chronic hepatitis C who failed IFN therapy. …”
Get full text

Peer-assisted telemedicine hepatitis-C treatment for people who use drugs in rural communities: a mixed methods study by Kim Hoffman, Gillian Leichtling, Sarah Shin, Andrew Seaman, Tonhi Gailey, Hunter C. Spencer, P. Todd Korthuis

“…Abstract Background The increase in opioid use disorder among young, nonurban people has fueled sharp rises in hepatitis C virus (HCV) infections. Innovative treatment models are needed that circumvent healthcare system barriers for people who use drugs (PWUD), particularly in rural areas. …”
Get full text

Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy by Xiping Ran, Xiping Ran, Yang Xu, Ying Wang, Cheng Zeng, Chen Gong, Ni Wang, Dachuan Cai, Dachuan Cai

Subjects: “…hepatitis C virus…”
Get full text

Efficacy and Safety of a Novel Pegylated Interferon Alpha-2a in Egyptian Patients with Genotype 4 Chronic Hepatitis C by Alaa Awad Taha, Ahmad El-Ray, Maged El-Ghannam, Bahaa Mounir

“…BACKGROUND: Hepatitis C virus (HCV) genotype 4 is a common infection in Egypt and is the leading cause of liver disease.…”
Get full text

Prevalence of hepatitis C virus antibodies and associated risks among residents in long-term assisted living facilities and shelters in Latvia by Ieva Tolmane, Ieva Siksaliete, Inga Upmace, Inga Bulmistre, Agita Jeruma, Inga Azina, Baiba Rozentale, Raimonds Sīmanis

Subjects: “…hepatitis c virus…”
Get full text

Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study by Hanan M. Fayed, Ali A. Ghweil, Mona M. AbdelMeguid

“…We aimed to investigate changes in the circulating monocyte phenotypes in response to Daclatasvir-Sofosbuvir (SOF/DCV) therapy in chronic hepatitis C (CHC) and relate findings to the viral kinetics and the fibrosis score. …”
Get full text

Mortality among Alaska Native Adults with Confirmed Hepatitis C Virus Infection Compared with the General Population in Alaska, 1995–2016 by Sara S. Bressler, Dana Bruden, Leisha D. Nolen, Michael G. Bruce, Lisa Towshend-Bulson, Philip Spradling, Brian J. McMahon

“…Background. Hepatitis C virus (HCV) infection incidence rates in the United States have increased since 2010 as a byproduct of the opioid crisis despite the introduction of direct-acting antiviral agents in 2013. …”
Get full text

Development of Virus-Like Particles (VLPs) for Hepatitis C Virus genotype 4: a novel approach for vaccine development in Egypt by Ahmed A. Ali, Rasha A. M. Azouz, Nahla A. Hussein, Reem El-Shenawy, Naiera M. Helmy, Yasmine S. El-Abd, Ashraf A. Tabll

Subjects: “…Hepatitis C Virus (HCV)…”
Get full text

Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease by Anna Maruyama, Trana Hussaini, Nilufar Partovi, Siegfried R. Erb, Vladimir Marquez Azalgara, Nadia Zalunardo, Neora Pick, Mark Hull, Eric M. Yoshida

“…Although major advances have occurred in treating patients with hepatitis C virus (HCV) with the development of new direct-acting antivirals (DAAs), treatment of liver transplant recipients with HCV, human immunodeficiency virus (HIV) coinfection, and renal disease is challenging due to the lack of efficacy and safety data in this population. …”
Get full text

Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada by Sergio M Borgia, Adenike Rowaiye

“…BACKGROUND: All oral, highly effective direct-acting antiviral combinations, such as sofosbuvir-ledipasvir, have recently been licensed in Canada but cost as much as $67,000 for a 12-week course of therapy, representing a major economic barrier to predominately single-payer health care systems such as that found in Ontario. In hepatitis C virus (HCV) genotype 1 noncirrhotic patients with a baseline viral load of <6×106 IU/mL, treatment with sofosbuvir-ledipasvir can be shortened to eight weeks without compromising ≥95% efficacy. …”
Get full text

Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study by D. T. Abrurakhmanov, V. G. Morozov, I. G. Nikitin, P. O. Bogomolov, N. I. Geyvandova, Ye. N. Bessonova, I. G. Bakulin, V. A. Isakov, K. V. Zhdanov, M. V. Mayevskaya, Ye. A. Nurmukhametova, E. Z. Burnevich, Ye. V. Chesnokov, V. D. Pasechnikov, A. Hill, I. Lonjon-Domanec, S. N. Kizhlo

“…In 153 patients with severe liver fibrosis caused by hepatitis C virus (genotype 1), on background of triple AVT with telaprevir high level of immediate virologic response and low level of the preterm treatment discontinuation was marked.…”
Get full text

Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients by Carla De Benedittis, Mattia Bellan, Martina Crevola, Elena Boin, Matteo Nazzareno Barbaglia, Venkata Ramana Mallela, Paolo Ravanini, Elisa Ceriani, Stefano Fangazio, Pier Paolo Sainaghi, Michela Emma Burlone, Rosalba Minisini, Mario Pirisi

“…The interplay between the two genes may explain some of the controversy on this topic and may be exploited to stratify HCC risk in hepatitis C.…”
Get full text

Results of the ORION open comparative randomized trial: evaluation of efficacy of the Russian drugs Altevir and Phosphogliv in combined treatment of chronic hepatitis C by V. T. Ivashkin, M. V. Mayevskaya, P. O. Bogomolov, I. G. Nikitin, A. O. Buyeverov, A. V. Lapshin

Subjects: “…chronic hepatitis c…”
Get full text